Participated · Series A · Mar 2026

Ateios Systems develops RaiCure™, a curing technology for lithium-ion battery electrodes that replaces slow, energy-intensive thermal curing and avoids PFAs. The RaiCure technology was developed in collaboration with Oak Ridge National Laboratory. The company aims to scale its electrode production and supply battery manufacturers at commercial scale by embedding its solution into existing production lines. Ateios has active commercial partnerships with companies including Eastman Kodak and Vianode and plans to use new funding to increase production capacity and manufacturing capabilities. Its recent $7.25M Series A follows earlier support including a million-dollar investment from the TitletownTech Start-up Draft and participation in ORNL’s Innovation Crossroads program.

Participated · Equity · Sep 2025

GeoH delivers a hybrid software-and-services solution that enables home-care agencies to manage staff scheduling, support clients, and handle billing within a single platform. Its end-to-end system combines practice-management tools with revenue-cycle and executive-management services, positioning the company as a full-service partner rather than a pure software vendor. GeoH reports that its revenue-cycle and executive-management offerings have helped customer agencies secure more than $275 million in funding to date, highlighting tangible value creation for its users. The company is led by CEO Tom Bumgardner and is headquartered in Indianapolis, Indiana. With the newest capital infusion, management plans to accelerate product development and scale operational capacity. While detailed financials such as annual revenue or user count were not disclosed, the sizable growth round suggests meaningful market traction and investor confidence in GeoH’s business model.

Participated · Series A · Jun 2024

OnStation is a Cleveland, OH-based provider of a collaborative digital stationing platform tailored to the heavy highway industry. Its mobile app centralizes communication and delivers location-based project records from bid to close, with instant jobsite stationing, milepost, and LRS capabilities. Users can overlay design layers on project maps and communicate via a custom chat platform that organizes and records project events at their locations. The platform is designed to boost productivity, enhance worker safety, and improve project quality across civil engineering and roadway projects. OnStation is available on the Apple App Store and Google Play and is supported on desktop systems. The company intends to use the newly raised funds to accelerate growth, expand its customer base, and enhance its platform. OnStation is a mobile application that enables better communication, location-based documentation, and streamlined issue tracking for road construction projects. The app serves as a complementary plugin to larger road construction tech solutions and provides access to project design files and contract documents. It is currently in use in 23 states and reports its customer base grew seven-fold over the past seven months. OnStation plans to use new funding to scale nationally, hire sales professionals and additional developers, and automate the project onboarding process. Leadership credits JumpStart Cleveland for four years of mentorship and support, and the product was built by founder and CTO Jake Bailosky based on his experience at the Ohio Department of Transportation. The company intends to add functionality and grow headcount to meet anticipated demand if federal infrastructure funding increases roadway projects.

Participated · Equity · Jan 2024

Adipo Therapeutics is a late-stage, preclinical biopharmaceutical company based at the Indiana Biosciences Research Institute in Indianapolis. Its lead asset, ADPO-002, is being developed to treat obesity and type 2 diabetes by converting energy-storing white adipose tissue into energy-burning brown adipose tissue, increasing energy expenditure and improving insulin resistance. Purdue noted ADPO-002 could be complementary to existing weight-loss and diabetes drugs. The company completed a $1.9M bridge round to complete critical studies demonstrating the therapy's mechanism in human fat. That bridge brings Adipo's total seed funding to $4 million. Adipo is currently in the midst of a $35 million Series A aimed at moving the treatment into a Phase 1 clinical development program. The company was founded by Dr. Meng Deng, who serves as president; Karen Wurster is CEO and the board recently added Dr. Michael Clayman.

Led · Equity · Jan 2024

NuvOx Therapeutics is a Tucson, Arizona–based clinical-stage biotechnology company developing NanO2, a first-in-class oxygen therapeutic platform to treat diseases where hypoxia is a driver. NanO2 is designed to improve oxygen flow from lungs to blood and from blood to tissue and has shown therapeutic effect in over 30 animal studies across seven indications. Positive clinical efficacy was demonstrated in two completed Phase Ib/IIa studies—as a radiosensitizer in glioblastoma multiforme and as a neuroprotectant in stroke—and the program has safety data in more than 2,000 subjects. NuvOx has commenced a Phase IIb glioblastoma multiforme trial in the United States and is preparing two additional clinical trials slated for late 2023. The program holds Orphan Drug Designation for glioblastoma multiforme and sickle cell disease and was reported to be the most effective oxygen therapeutic among 74 clinical-stage compounds. The company has attracted $14 million in non-dilutive funding from the NIH, Department of Defense and other government funders and recently completed a bridge round in which VisionTech Angels invested $196,500 following a $10.4 million Series A. NuvOx Pharma develops an intravenous oxygen-delivery platform based on dodecafluoropentane emulsion (DDFPe), a contrasting agent repurposed to deliver O2 to hypoxic tissues. Its lead program is poised to enter Phase 2 trials in glioblastoma multiforme (GBM) to restore tumor oxygenation and improve response to cancer therapies. Additional programs target acute stroke neuroprotection and treatment of sickle cell crises, and the company positions DDFPe as a platform for multiple hypoxia-related indications. The DDFPe formulation was previously approved in Europe and used in roughly 2,200 patients; FDA has granted permission to reference that historical data for new indications. Financially, NuvOx has not taken venture capital — it has raised $6 million from angel investors, including the Desert Angels, and supplemented that with grants from the NIH, the State of Arkansas, the Arizona Commerce Authority, the military, and other sources. To conserve cash the company uses capital-efficient practices: employees accept equity as part of compensation, the CEO has worked for equity, and company rent has been paid in equity.